Looking for novel anticancer agents, researchers from Ho Chi Minh City University of Science (Vietnam) and colleagues recently identified KTt-45, a compound derived from 6-prenylnaringenin, as a promising candidate.
Medilink Therapeutics (Suzhou) Co. Ltd. has entered into a worldwide collaboration and license agreement with F. Hoffmann-La Roche Ltd. for the development of YL-211, a next-generation antibody-drug conjugate candidate targeting proto-oncogene c-Met for solid tumors.
Obi Pharma Inc. has received FDA clearance for its IND application to conduct a phase I/II study of OBI-992, a novel antibody-drug conjugate (ADC) cancer therapy targeting TROP2. The trial will open shortly and aims to enroll patients with advanced solid tumors, including non-small-cell lung cancer, small-cell lung cancer and gastric cancer, although several other cancers are also potential targets.
Bispecific antibodies acting through CEACAM5/CD3 targeting have limited efficacy due to dose-limiting toxicities, insufficient T-cell activation and formation of anti-drug antibodies (ADAs). Researchers from Novimmune SA and Lampkap Bio Alpha AG have published data on a CEACM5/CD3 bispecific antibody, NILK-2301, which is formed by a heavy chain plus two different light chains (kappa and lambda body) as a potential immunotherapeutic with better efficacy and lower potential for ADA formation.
Researchers at Hitgen Ltd. and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. have described Bcl-2-like protein 1 (Bcl-xL; Bcl-X; BCL2L1) inhibitors reported to be useful for the treatment of cancer and autoimmune diseases.
Domain Therapeutics SA has disclosed proteinase-activated receptor 2 (PAR2; F2RL1) antagonists reported to be useful for the treatment of allergy, autoimmune and metabolic diseases, cardiovascular disorders, dermatological disorders, inflammatory disorders, pain and cancer.
The contribution of alternative RNA splicing in the progression of pancreatic ductal adenocarcinoma (PDAC) has not been deeply explored. In a recent study, the RNA-binding protein RNA binding fox-1 homolog 2 (RBFOX2) was investigated, since its role in modulating alternative splicing in PDAC is not well understood.
RSS
